Endo International plc (NASDAQ: ENDP), a highly focused generics and specialty branded pharmaceutical company, announced on Wednesday that it has named Mark G Barberio as its new director.
Barberio has also been appointed to the company's Audit and Nominating and Governance Committees.
Barberio is the principal of Markapital LLC. Prior to founding Markapital, he led Mark IV LLC where he served in a number of leadership positions, including as its co-chief executive officer and chief financial officer.
Paul Campanelli, Endo's chairman, president and chief executive officer, said 'In addition to Mark's senior executive leadership experience, Mark's operations, finance and strategic planning perspective on corporate growth will provide valuable insight to the board. We are pleased to welcome him to our board.'
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling